MedTrace Logo

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

NCT05612100 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2026-04-30

No results posted yet for this study

Summary

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

Conditions

  • Breast Carcinoma

Interventions

OTHER

Survey Administration

Complete alopecia surveys

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Questionnaire Administration

Complete alopecia questionnaires

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Cathcart-Rake, M.D. · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-06
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612100 on ClinicalTrials.gov